The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.
Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.
Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
GLP-1 medications, initially developed for diabetes, are revolutionizing health outcomes, offering remarkable benefits for inflammation, joint pain, and even mental outlook, alongside significant weight loss.
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
